• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Meta-Analysis Results: Invasive Prenatal Testing in Twin Pregnancies and Fetal Loss

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Di Masco et al. (Ultrasound in Obstetrics & Gynecology, 2020) assessed the rate of fetal loss following amniocentesis or CVS in twin pregnancy

METHODS:

  • Systematic review and meta-analysis
  • Data sources
    • MEDLINE, EMBASE and Cochrane databases
  • Inclusion criteria
    • Prospective and retrospective studies that reported procedure-related complications following amniocentesis or CVS in twin pregnancy
  • Data analysis
    • Head-to-head meta-analyses to directly compare each outcome between
      • Amniocentesis vs no amniocentesis
      • CVS vs no CVS
    • Pooled risk differences (RD) computed between exposed (invasive testing) and unexposed
  • Primary outcome
    • Rate of procedure-related fetal loss
  • Secondary outcomes
    • Fetal loss occurring <24 weeks of gestation
    • Fetal loss occurring within 4 weeks of the procedure

RESULTS:

  • 16 studies
    • Invasive procedure: 3419 twin pregnancies
    • Control (no invasive procedure): 2517 twin pregnancies

Amniocentesis

  • There was a higher risk for overall fetal loss in those undergoing amniocentesis in twins (P = 0.04)
    • Odds ratio (OR) 1.46 | RD 0.013
  • No differences were found for the following
    • Fetal loss <24 weeks
      • OR 1.59 (P = 0.06) | RD 0.010 (P = 0.11)
    • Fetal loss within 4 weeks after the procedure
      • OR 1.38 (P = 0.3) | RD 0.003 (P = 0.8)
    • Pooled rate of fetal loss
      • Amniocentesis: 2.4% (95% CI, 1.4 to 3.6%)
      • Control: 2.4% (95% CI, 0.9 to 4.6%)

Chorionic villus sampling

  • No differences were found for the following
    • Fetal loss
      • OR 1.61 (P = 0.5) | RD 0.003 (P = 0.8)
    • Fetal loss <24 weeks of gestation
      • OR 1.61 (P = 0.5) | RD 0.003 (P = 0.8)
  • Pooled rate of fetal loss
    • CVS: 2.0% (95% CI, 0.0 to 6.5%)
    • Control: 1.8% (95% CI, 0.3 to 4.2%)

CONCLUSION:

  • The risk of fetal loss following invasive sampling procedures in twin pregnancies is not as high as previously reported
  • The rate of fetal loss before 24 weeks and within 4 weeks of the procedure was not different than the background (control) risk
  • The authors conclude

These data are intuitively helpful when counseling parents about the safety of the procedure, as the woman can be reassured that the overall risk of fetal loss is low

Learn More – Primary Sources:

Risk of fetal loss following amniocentesis or chorionic villus sampling in twin pregnancy: systematic review and meta‐analysis

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Should Amniocentesis or Chorionic Villus Sampling Be Offered to All Pregnant Women?
Does Noninvasive Screening Result in Fewer Miscarriages When Compared to Amniocentesis?
Do Amniocentesis or CVS Really Lead to Increased Risk of Miscarriage? 
Does Single or Double Needle Insertion in Twin Amniocentesis Influence Complication Risk?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site